Kornimate/medical-research-clean huggingface dataset:
care transition intervention for patients with cancer

Conditions: Advanced Cancer; Home Care, Hospital-Based

Summary: this research study is investigating an intervention called continuity of care under management by video visits (continuum-v). continuum-v involves a video visit with an oncology nurse practitioner within three business days of hospital discharge for patients with advanced cancer with the goal of reducing burdensome care transitions after hospitalization, including hospital readmissions.

this is a single-site, single-arm pilot trial to assess the feasibility and acceptability of a continuum-v for patients with advanced cancer the research study procedures include: * a video visit with a nurse practitioner within three business days of hospital discharge * questionnaires asking about demographic information (e.g. sex, ethnicity, income) and participant experience with cancer (e.g. symptoms and confidence in managing their health condition) * a satisfaction survey to assess the participants' impressions of the intervention and any suggestions the participants may have * data collection from their medical record * one time interview of participant and clinician for feedback on continuum-v participants will be in this research study for up to 45 days after hospital discharge. 54 patients and 4 clinicians took part in this research study. the conquer cancer foundation and the rising tide foundation for clinical cancer research are supporting this research study by providing a career pathway grant in symptom management to support the research team.

Eligibility criteria:
inclusion criteria: 1. age \>= 18 years 2. unplanned admission to the oncology service at massachusetts general hospital (mgh) 3. known diagnosis of advanced breast, thoracic, genitourinary, or gastrointestinal cancers. advanced cancer defined as not being treated with curative intent as determined by clinic notes and chemotherapy order entry. 4. receiving ongoing oncology care at mgh 5. verbal fluency in english 6. must have internet/wifi/cellular data access exclusion criteria: 1. admitted electively 2. discharged to a location other than home or expired during admission 3. discharged with hospice services

Keywords: advanced cancer home care, hospital-based transitions of care care transition intervention
imaging lymphatic/cerebrospinal fluid (csf) drainage from the head and neck in persons with traumatic brain injury: demonstration of feasibility and evaluation of manual therapy to improve drainage and facilitate cognitive recovery

Conditions: Trauma, Brain; Neuroinflammation

Summary: the purpose of this study is to determine whether a course of daily manual lymphatic drainage over the course of 5 days can improve lymphatic drainage function and cognitive outcomes and to determine whether single sessions of manual lymphatic drainage improves lymphatic drainage in moderate to severe traumatic brain injury (tbi) patients.


Eligibility criteria:
inclusion criteria: * female participants must complete the female enrollment form. those subjects of childbearing potential must have a negative urine pregnancy within 36 hours of study drug administration and also agree to use one of the medically accepted methods of contraception listed on the form for a period of one month following the study. female subjects of non-childbearing potential, defined as physiologically incapable of becoming pregnant, must meet the criteria listed on the female enrollment form, but are not restricted to the use of contraception following study participation. * participants must be able to sit upright for periods of 30 minutes. * participants should have a body mass index between 19 and 30 kg/m2 * initial post-resuscitation glasgow coma scale score following blunt head trauma of 3 to 12 or coma (not due to sedation) greater than 6 hours. emergence from post-traumatic amnesia as documented by serial administration of the orientation-log or galveston orientation and amnesia test * have an anticipated hospital length of stay of 5 days or more following screening and consent. * able to provide consent. exclusion criteria: * women who are pregnant or breast-feeding * persons who are known to be allergic to iodine * persons who have extensive soft tissue damage to the neck region, including carotid artery dissection, spinal cord injury, or other conditions, that makes lymphatic drainage techniques undesirable. * women who are of child bearing potential who do not agree to use medically acceptable contraceptives for one month following the study. * subjects who are participating in another interventional trial.

Keywords: traumatic brain injury lymphatic drainage cerebrospinal fluid
pudendal nerve block in vaginal surgery

Conditions: Nerve Block; Pain, Postoperative; Pelvic Floor Disorders; Pelvic Organ Prolapse; Pudendal Neuralgia; Surgery

Summary: the objective of this this randomized controlled study is to determine whether a pudendal nerve block at the time of vaginal surgery is associated with improved postoperative pain control and decrease opioid consumption compared to a sham pudendal nerve block in patients undergoing vaginal surgery.


Eligibility criteria:
inclusion criteria: * consenting, english speaking women between ages 18 and 80 who will undergo vaginal surgery * ability to read vas scores * specific vaginal procedures include, but are not limited to: perineoplasty complete vaginectomy le forte colpocleisis anterior repair, posterior repair, and/or enterocele repair transvaginal mesh use transvaginal mesh excision sacrospinous ligament fixation uterosacral ligament suspension vaginal paravaginal defect repair midurethral sling placement sphincteroplasty vaginal hysterectomy, with or without removal of tube(s) and/or ovary(s), with or without repair of enterocele exclusion criteria: * history of chronic pelvic pain * currently taking sedatives * liver disease * renal disease * women who did not consent for the study. * intraoperative concern for increased blood loss * unable to speak english * unable to understand vas scores * undergoing concomitant abdominal or laparoscopic procedures * allergy to bupivacaine or triamcinolone * planned abdominal or laparoscopic procedures. * patients who are ineligible for non-narcotic pain medications, such as an allergy to acetaminophen or nsaids
evaluation of the safety and tolerability of kh001 in dentin hypersensitivity patients

Conditions: Dentin Sensitivity

Summary: this is a phase 1/2a study in dentin hypersensitivity patients to assess the safety, tolerability, efficacy and pharmacokinetics of single and multiple doses of kh001.


Eligibility criteria:
\[inclusion criteria\] 1. subjects must be fully aware of the purpose and the content of the study, and the characteristics of the investigational product to sign written consent of their free will to take part in the study; 2. subjects having at least 20 natural teeth and two teeth that could be assessed 3. subjects is diagnosed with dentin hypersensitivity, has experienced dental symptoms of two or more teeth \[exclusion criteria\] 1. subjects is allergic to the active substance or other excipients used in the investigational product 2. subjects has any history of clinically significant allergy, such as drug allergy, asthma, eczema, or anaphylaxis 3. subjects has any disease related to dentin hypersensitivity 4. subjects taking anti-inflammatory analgesic drugs

Keywords: dentin regeneration hypersensitivity sensitivity tooth sensitivity
comparing the adr with air insufflation, water immersion and water exchange during two-endoscopist colonoscopy

Conditions: Adenoma

Summary: interval (missed) cancers and lower than expected mortality reduction of proximal colon cancers in the united states and elsewhere after screening colonoscopy drew attention to quality indicators. missed adenomas which are more likely to be in the proximal colon may be contributing factors. an independent predictor of the risk of interval cancers is adenoma detection rate. in pilot observations, the investigators showed that water exchange enhanced adenoma detection in the right colon (cecum to hepatic flexure). this prospective, randomized controlled trial will compare water exchange with water immersion and traditional air insufflation in patients undergoing colonoscopy. the investigators test the hypothesis that compared with air insufflation and water immersion, water exchange produces a significantly higher adenoma detection rate in the right colon

all of the procedures will be recorded and stored as digital files.

Eligibility criteria:
inclusion criteria: * patients undergoing colonoscopy performed by the participating endoscopists exclusion criteria: * obstructive lesions of the colon known before colonoscopy * massive ascites * past history of partial colectomy * refusal to provide written informed consent

Keywords: adenoma detection rate colonoscopy water exchange
radiofrequency versus laser ablation for hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular; Neoplasms, Liver

Summary: the purpose of this study is to prospectively compare percutaneous radiofrequency ablation (rfa) versus percutaneous laser ablation (la) for the treatment of small hepatocellular carcinoma in patients with cirrhosis.

percutaneous ablation is a safe and effective therapy for cirrhotic patients with hcc when resection or liver transplantation is not possible. among the various percutaneous local ablative therapies, radiofrequency ablation (rfa) has attracted the greatest interest because of its effectiveness and safety for single hcc ≤ 5.0cm or ≤3 hcc nodules ≤3cm. some studies have shown that laser ablation (la) may be as effective as rfa in the treatment of hcc. however, rfa and la are different techniques and, in different cases (for example: size or site of hcc nodule), each of these procedures may have some advantages or disadvantages. therefore there is the need for a prospective randomized controlled study to compare rfa and la in patients with small hcc.

Eligibility criteria:
inclusion criteria: * patients with unresectable hcc or who refused surgery * a solitary hcc ≤ 5.0cm in diameter, or multiple hcc ≤ 3 lesions, each ≤ 3.0cm in diameter * child-pugh class a or b * platelet count correctable to \> 40,000/mm3, inr correctable to \< 2.0 * no previous treatment of hcc exclusion criteria: * other severe concomitant diseases that may reduce life expectancy * history of encephalopathy, refractory ascites or variceal bleeding * vascular invasion or extrahepatic metastasis * human immunodeficiency virus (hiv) infection * substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study
fr in stored plasma

Conditions: Ovarian Cancer

Summary: the folate receptor (fr) is a cell over expressed on the surface of certain cancers, this occurs most frequently in ovarian cancers. some normal tissues also express the fr, however in these normal tissues, the fr is usually located on the tissue surface that is inaccessible to circulating drugs. as such, drugs which target the fr may potentially be used to target cancers which overexpress the fr while reducing toxicity to normal tissues. therefore the ability to measure fr levels from different cancer types may help to select patients who are most likely to benefit from treatment with fr targeted therapies. once such drug bgc945 is currently being tested in preclinical study at the institute of cancer research

fr may be released from the cancer cells in the blood. we have developed a method in the laboratory which has been able to measure the fr obtained from cancer cells in culture which has been added into blood. we would like to study if this method is able to measure the fr in stored plasma samples obtained from patients with ovarian cancer, so that it may be developed as a method for selecting patients for fr-target treatments such as bgc 945.

Eligibility criteria:
inclusion criteria: * patients with ovarian cancer who have given informed consent to have blood collected for the plasma bank in the 'pharmacogenetics and proteomics studies in patients receiving novel anticaner agents' study. exclusion criteria: * patients who have withdrawn consent form their blood stored within the 'pharmacogenetics and proteomics studies in patients receiving novel anticancer agents' study to be used for research.

Keywords: ovarian cancer, folate receptor, plasma
randomisation to endobarrier alone versus with incretin analogue in sustained diabesity (revise-diabesity)

Conditions: Type 2 Diabetes; Obesity; Diabesity

Summary: new effective non-surgical treatments are needed for patients whose obesity and type 2 diabetes (t2dm) do not respond to current medical therapies. we propose a randomised controlled trial of endobarrier, an implantable intestinal device that separates ingested food from contacting the first 60cm of intestine where sited and that mimics some of the clinical effects of bariatric surgery (improved metabolic control with weight loss) with or without continued use of the glp-1 receptor agonist (glp-1ra) liraglutide 1.2mg vs liraglutide 1.8mg without the device in obese patients with t2dm who remain with suboptimal glycaemic control despite current conventional diabetes treatment, in an nhs setting. seventy-two patients with t2dm and obesity (hba1c≥7.5%, bmi≥35kg/m2) despite previous glp-1ra therapy will be studied over 24 months and randomised to receive endobarrier with continued liraglutide 1.2mg for 12 months; endobarrier alone for 12 months; or liraglutide 1.8mg without endobarrier. we will investigate potential mechanisms of action and their time course as part of the study by repeated measures of: 1. insulin resistance measures, gut peptides, bile acids; 2. energy intake and nutritional composition; 3. liver fat stores, 4. intestinal inflammation and permeability measures. the data will inform clinical use of the device and development of new treatments for t2dm and obesity.


Eligibility criteria:
inclusion criteria: * type 2 diabetes with latest hba1c ≥7.5% (≥58mmol/mol) * obesity with latest bmi ≥35 kg/m2 (≥30 kg/m2 for those of south asian origin) * liraglutide therapy for at least 6 months - hba1c and weight trend data should be available * stable weight and hba1c in preceding 3 months (\<3 kg reduction in weight and \<0.3% reduction in hba1c) exclusion criteria: * \<18 years of age * abnormal intestinal anatomy e.g. crohn's disease * contraindication to oesophago-gastroduodenoscopy * previous bariatric surgery or bowel surgery * active infection * anticoagulation therapy which cannot be discontinued/ coagulopathy inr \>1.3 * egfr \<30 * known portal hypertension * previous pancreatitis or amylase \> 3 times the upper limit of normal * uncontrolled cardiovascular disease * lactating or pregnant females * patients taking aspirin in whom it should continue (e.g. active ischaemic heart disease or cerebrovascular disease) * excess anaesthetic risk as identified by the anaesthetist or investigator (e.g. uncontrolled obstructive sleep apnoea)

Keywords: endobarrier duodenal-jejunal bypass liner glucagon-like peptide-1 receptor agonist liraglutide diabesity type 2 diabetes obesity
study on vaginal microecology and cervical local immune function in patients with uterine fibroids of childbearing age

Conditions: Uterine Fibroids

Summary: the study participants are patients with uterine fibroids and healthy physical examination subjects from the first affiliated hospital of shandong first medical university (shandong qianfoshan hospital). the main purpose of this study is to analyze the correlation between uterine fibroids and vaginal microecology and cervical local immune function in patients of childbearing age.

(1) in this study, 150 women of childbearing age who are diagnosed with uterine fibroids in the first affiliated hospital of shandong first medical university (shandong qianfoshan hospital) are selected as the study group; the differences of vaginal microenvironment and cervical local immune function are compared between 150 healthy women of childbearing age in the same period. (2) after the patients are enrolled, the general information (age, height, weight), menstrual status (age of menarche, menstrual period, cycle, bleeding pattern), clinical manifestations (abnormal uterine bleeding, infertility, abdominal pain), and previous medical history (hypertension, thyroid disease, etc.) of 150 patients with uterine fibroids will be collected. after the end of the first part of the experiment, 150 patients with uterine fibroids will be grouped according to vaginal microecological diagnosis, and the clinical characteristics of patients with uterine fibroids will be analyzed and compared.

Eligibility criteria:
inclusion criteria: study group inclusion criteria: * age 20-49 years old * premenopausal * clinical diagnosis of uterine myoma * cervical liquid-based cytology and human papillomavirus typing test are negative healthy control group: * age 20-49 years old * premenopausal * uterine b-ultrasonography is normal * cervical liquid-based cytology and human papillomavirus typing test are negative * no vaginal infection exclusion criteria: exclusion criteria of the study group: * used antibiotics, hormones, immunosuppressants and regulators within 1 month * sex, vaginal irrigation or applied medicine 3 days before the vaginal discharge sampling * pregnant, lactating or menstruating women * uterus and uterine adnexa have other lesions exclusion criteria of healthy control group: * used antibiotics, hormones, immunosuppressants and regulators within 1 month * sex, vaginal irrigation or applied medicine 3 days before the vaginal discharge sampling * pregnant, lactating or menstruating women

Keywords: uterine fibroids vaginal microecology cervical local immune function childbearing age
thiol/disulphide homeostasis and preeclampsia

Conditions: Preeclampsia

Summary: objective: to evaluate serum evaluate thiol/ disulfide levels in preeclampsia and address its relationship with its severity. methods: this prospective study will include 50 pregnancies complicated with preeclampsia and 50 healthy pregnancies. the blood for analysis will obtain at the admission and serum thiol/ disulfide levels will measure using commercially available reagent kits. the continuous values were evaluated using student's t-test, and categorical values were evaluated using the chi-square test. p values \< .05 were accepted as significant.

this is an observational prospective cohort study will conduct at obstetrics and gynecology department of cengiz gokcek obstetrics and children's hospital between april and october 2019. one hundred women will enrol in the study in two groups. we will consecutively recruit 50 pregnancies complicated with preeclampsia, and 50 healthy pregnancies will select for the control group. all patients will give their oral and written informed consent before their inclusion in the study. the protocol was approved by the ethics committee for clinical research of gaziantep university (reference number: 2019/147). the study strictly will adhere to the principles of the declaration of helsinki.

Eligibility criteria:
inclusion criteria: * preeclampsia * healthy pregnancy exclusion criteria: * pregnant women with any systemic condition (such as chronic hypertension, diabetes mellitus, thyroid diseases, liver and kidney diseases) * women with a history of drug use throughout pregnancy * history of medication for pe treatment at the time of first admission * patients who had fetal congenital abnormalities or genetic syndromes * multiple gestation * active labor

Keywords: oxidative stress mercaptan severity
mhealth incentivized adherence plus patient navigation

Conditions: Opioid Use Disorder; Medication Adherence; Polysubstance Drug Use (Indiscriminate Drug Use); Methamphetamine-dependence

Summary: polysubstance use involving opioids and methamphetamine is emerging as a new public health crisis. patients with opioids and methamphetamine use often experience serious medical complications requiring hospitalization, which provides an opportunity to offer addiction treatment. yet linkage to outpatient treatment post-discharge is suboptimal and methamphetamine exacerbates outcomes. the investigators propose to pilot test "mhealth incentivized adherence plus patient navigation" (miapp) to promote treatment linkage and retention for patients with opioid use disorder (oud) and methamphetamine use who initiate buprenorphine in the hospital. the investigators aim is to perform a two-arm, pilot randomized clinical trial (n=40) comparing miapp + treatment-as-usual (tau) versus tau alone on outpatient medication for opioid use disorder (moud) linkage within 30 days (primary) and 90-day retention on medications (secondary) among hospitalized patients with oud and methamphetamine use.


Eligibility criteria:
inclusion criteria: * adult greater than or equal to 18 years of age * admitted to harborview medical center (hmc) on any inpatient service * initiated on buprenorphine for oud while in the hospital or at the time of discharge and planning to continue outpatient * used methamphetamine within the past 30 days (any route of administration or frequency) * willing to be randomized to video-dot * willing and able to use a smartphone (study can provide) and work with patient navigator * discharge setting does not preclude the use of video-dot (i.e., nursing home, inpatient psychiatry, etc.) exclusion criteria: * unable or unwilling to use smartphone (phones to be provided when needed) * cognitive impairment (acute or chronic) resulting in inability to provide informed consent * currently incarcerated and will discharge to jail or prison * plans to discontinue buprenorphine in the near future (\<3 months) * lives far away such that cannot keep study visit at 30 days post-discharge * not english speaking * behavioral risk per discretion of research staff